vs

Side-by-side financial comparison of Chaince Digital Holdings Inc. (CD) and Humacyte, Inc. (HUMA). Click either name above to swap in a different company.

Humacyte, Inc. is the larger business by last-quarter revenue ($467.0K vs $466.6K, roughly 1.0× Chaince Digital Holdings Inc.).

Humacyte, Inc. is a clinical-stage biotechnology firm focused on developing and commercializing universally implantable off-the-shelf bioengineered human tissues and therapeutic products. Its core offerings target unmet needs in vascular care, trauma treatment and regenerative medicine, serving patients and healthcare partners worldwide.

CD vs HUMA — Head-to-Head

Bigger by revenue
HUMA
HUMA
1.0× larger
HUMA
$467.0K
$466.6K
CD

Income Statement — Q2 FY2025 vs Q4 FY2025

Metric
CD
CD
HUMA
HUMA
Revenue
$466.6K
$467.0K
Net Profit
$-3.0M
Gross Margin
-1844.8%
Operating Margin
-665.1%
-6603.0%
Net Margin
-640.5%
Revenue YoY
Net Profit YoY
EPS (diluted)
$-0.05
$-0.19

Green = leading value per metric. Periods may differ when fiscal calendars don't align.

8-Quarter Revenue & Profit Trend

Side-by-side quarterly history. Quarters aligned by calendar period so offset fiscal years line up.

Revenue
CD
CD
HUMA
HUMA
Q4 25
$467.0K
Q3 25
$753.0K
Q2 25
$466.6K
$301.0K
Q1 25
$517.0K
Q3 24
$0
Q2 24
$0
Q1 24
$0
Net Profit
CD
CD
HUMA
HUMA
Q4 25
Q3 25
$-17.5M
Q2 25
$-3.0M
$-37.7M
Q1 25
$39.1M
Q3 24
$-39.2M
Q2 24
$-56.7M
Q1 24
$-31.9M
Gross Margin
CD
CD
HUMA
HUMA
Q4 25
-1844.8%
Q3 25
65.5%
Q2 25
29.2%
Q1 25
71.6%
Q3 24
Q2 24
Q1 24
Operating Margin
CD
CD
HUMA
HUMA
Q4 25
-6603.0%
Q3 25
-3239.0%
Q2 25
-665.1%
-9876.1%
Q1 25
-4484.3%
Q3 24
Q2 24
Q1 24
Net Margin
CD
CD
HUMA
HUMA
Q4 25
Q3 25
-2325.4%
Q2 25
-640.5%
-12511.0%
Q1 25
7570.4%
Q3 24
Q2 24
Q1 24
EPS (diluted)
CD
CD
HUMA
HUMA
Q4 25
$-0.19
Q3 25
$-0.11
Q2 25
$-0.05
$-0.24
Q1 25
$0.28
Q3 24
$-0.33
Q2 24
$-0.48
Q1 24
$-0.29

Balance Sheet & Financial Strength

Snapshot of each company's liquidity, leverage and book value from the latest quarter.

Metric
CD
CD
HUMA
HUMA
Cash + ST InvestmentsLiquidity on hand
$27.2M
$50.5M
Total DebtLower is stronger
$35.4M
Stockholders' EquityBook value
$29.4M
$3.1M
Total Assets
$36.6M
$116.4M
Debt / EquityLower = less leverage
11.40×

8-quarter trend — quarters aligned by calendar period.

Cash + ST Investments
CD
CD
HUMA
HUMA
Q4 25
$50.5M
Q3 25
$19.5M
Q2 25
$27.2M
$38.0M
Q1 25
$62.8M
Q3 24
$20.6M
Q2 24
$93.6M
Q1 24
$115.5M
Total Debt
CD
CD
HUMA
HUMA
Q4 25
$35.4M
Q3 25
Q2 25
Q1 25
Q3 24
Q2 24
Q1 24
Stockholders' Equity
CD
CD
HUMA
HUMA
Q4 25
$3.1M
Q3 25
$-4.8M
Q2 25
$29.4M
$4.1M
Q1 25
$36.0M
Q3 24
$-63.7M
Q2 24
$-28.3M
Q1 24
$26.2M
Total Assets
CD
CD
HUMA
HUMA
Q4 25
$116.4M
Q3 25
$91.5M
Q2 25
$36.6M
$138.8M
Q1 25
$162.6M
Q3 24
$114.8M
Q2 24
$138.3M
Q1 24
$161.5M
Debt / Equity
CD
CD
HUMA
HUMA
Q4 25
11.40×
Q3 25
Q2 25
Q1 25
Q3 24
Q2 24
Q1 24

Cash Flow & Capital Efficiency

How much cash each business actually produces after reinvestment. Cash flow is harder to manipulate than net income.

Metric
CD
CD
HUMA
HUMA
Operating Cash FlowLast quarter
$-1.3M
$-26.1M
Free Cash FlowOCF − Capex
$-26.2M
FCF MarginFCF / Revenue
-5602.4%
Capex IntensityCapex / Revenue
8.4%
Cash ConversionOCF / Net Profit
TTM Free Cash FlowTrailing 4 quarters
$-105.9M

8-quarter trend — quarters aligned by calendar period.

Operating Cash Flow
CD
CD
HUMA
HUMA
Q4 25
$-26.1M
Q3 25
$-23.9M
Q2 25
$-1.3M
$-26.4M
Q1 25
$-28.6M
Q3 24
$-22.9M
Q2 24
$-21.3M
Q1 24
$-27.3M
Free Cash Flow
CD
CD
HUMA
HUMA
Q4 25
$-26.2M
Q3 25
$-24.0M
Q2 25
$-27.0M
Q1 25
$-28.8M
Q3 24
$-23.8M
Q2 24
$-21.5M
Q1 24
$-27.7M
FCF Margin
CD
CD
HUMA
HUMA
Q4 25
-5602.4%
Q3 25
-3181.0%
Q2 25
-8963.8%
Q1 25
-5576.2%
Q3 24
Q2 24
Q1 24
Capex Intensity
CD
CD
HUMA
HUMA
Q4 25
8.4%
Q3 25
6.5%
Q2 25
188.7%
Q1 25
44.1%
Q3 24
Q2 24
Q1 24
Cash Conversion
CD
CD
HUMA
HUMA
Q4 25
Q3 25
Q2 25
Q1 25
-0.73×
Q3 24
Q2 24
Q1 24

Financial Flow Comparison

Revenue → gross profit → operating profit → net profit for each company.

Related Comparisons